

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/122765 A2

(51) International Patent Classification:
Not classified

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2021/084659

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
07 December 2021 (07.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/122,042 07 December 2020 (07.12.2020) US

(71) Applicants: **GENMAB A/S** [DK/DK]; Kalvebod Brygge
43, DK-1560 Copenhagen V (DK). **BIONTECH SE**
[DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE An der Gold-
grube 12, 55131 Mainz (DE). **MUIK, Alexander**; c/o
BioNTech SE An der Goldgrube 12, 55131 Mainz (DE).
FORSSMANN, Ulf; c/o Genmab A/S Kalvebod Brygge 43,
DK-1560 Copenhagen V (DK). **JURE-KUNKEL, Maria**;
c/o Genmab US, Inc. 777 Scudders Mill Road, Plainsboro,
New Jersey 08536 (US). **GUPTA, Manish**; c/o Genmab
US, Inc. 777 Scudders Mill Road, Plainsboro, New Jersey
08536 (US). **AHMADI, Tahamtan**; c/o Genmab US, Inc.
777 Scudders Mill Road, Plainsboro, New Jersey 08536
(US). **AMIRI, Kathy**; c/o Genmab US, Inc. 777 Scudders
Mill Road, Plainsboro, New Jersey 08536 (US). **BAJAJ,**
Gaurav; c/o Genmab US, Inc. 777 Scudders Mill Road,
Plainsboro, New Jersey 08536 (US).

(74) Agent: **GENMAB A/S**; Kalvebod Brygge 43, DK-1560
Copenhagen V (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTIBODY AND TAXANE COMBINATION THERAPY

(57) Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

WO 2022/122765 A2